LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Presents Latest Innovations and Trends in Clinical Diagnostics and POC Testing

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The Atellica HEMA 570 and 580 Analyzers (Photo courtesy of Siemens Healthineers)
Image: The Atellica HEMA 570 and 580 Analyzers (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) is presenting its newest innovations at WorldLab–EuroMedLab Roma 2023 that aim to help deliver high-value care, and confidently provide the answers expected by clinicians and patients. A team of company experts is demonstrating innovations and trends in clinical diagnostics and point-of-care testing at the industry event.

On display at the Siemens booth are the company’s two new solutions for high-volume hematology testing, the Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. Both hematology analyzers offer integrated automation and intelligence to eliminate barriers that hamper workflow efficiency and deliver faster patient results. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers have a throughput of up to 120 tests per hour and feature user-friendly designs that significantly reduce time-consuming daily maintenance and support rapid reagent changes.

The Atellica HEMA 570 and Atellica HEMA 580 Analyzers adopt advanced data management capabilities to eliminate the expertise gap and empower staff of all skill levels during result interpretations. In order to save time and provide physicians with information more quickly, normal results that do not violate pre-established criteria are released directly into a laboratory information system using the analyzers' rules-based auto-validation capability. Abnormalities are flagged and coded on the basis of severity to provide a clear indication of which patient samples need closer attention from the technician. In case results require follow-up actions like dilutions or slide reviews, standardized guidance is displayed to ensure that staff performs the next steps in accordance with lab protocols.

"We hear from labs that they need agility, reliability, and speed," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The Atellica HEMA analyzers combine workflow improvements with demonstrated technology to bring hematology testing into the future. We're delivering the breakthroughs labs need to produce quality patient results faster."

Related Links:
Siemens Healthineers 

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.